AndreaBozzo/ceres-open-data-index huggingface dataset:
Resources for Populations Served by ACF Programs

In support of ACF’s mission and strategic plan, ACF has developed a set of materials intended for specific subgroups of program participants, prospective participants, and their communities to help them understand the array of programs and resources that may be able to assist them. These one- to two-page overviews are available below.

Who should use these materials?

Why use these materials?

Many families, individuals, and communities may not know about the full range of services and resources that are available to and could benefit them. These materials can help them find and access helpful supports tailored to their particular situation.

How should these materials be shared?

Metadata-only record linking to the original dataset. Open original dataset below.
Delineation of RAID1, the RACK1 interaction domain located within the unique N-terminal region of the cAMP-specific phosphodiesterase, PDE4D5

Background
          The cyclic AMP specific phosphodiesterase, PDE4D5 interacts with the β-propeller protein RACK1 to form a signaling scaffold complex in cells. Two-hybrid analysis of truncation and mutant constructs of the unique N-terminal region of the cAMP-specific phosphodiesterase, PDE4D5 were used to define a domain conferring interaction with the signaling scaffold protein, RACK1.
        
        
          Results
          Truncation and mutagenesis approaches showed that the RACK1-interacting domain on PDE4D5 comprised a cluster of residues provided by Asn-22/Pro-23/Trp-24/Asn-26 together with a series of hydrophobic amino acids, namely Leu-29, Val-30, Leu-33, Leu-37 and Leu-38 in a 'Leu-Xaa-Xaa-Xaa-Leu' repeat. This was done by 2-hybrid analyses and then confirmed in biochemical pull down analyses using GST-RACK1 and mutant PDE4D5 forms expressed in COS cells. Mutation of Arg-34, to alanine, in PDE4D5 attenuated its interaction with RACK1 both in 2-hybrid screens and in pull down analyses. A 38-mer peptide, whose sequence reflected residues 12 through 49 of PDE4D5, bound to RACK1 with similar affinity to native PDE4D5 itself (Ka circa 6 nM).
        
        
          Conclusions
          The RACK1 Interaction Domain on PDE4D5, that we here call RAID1, is proposed to form an amphipathic helical structure that we suggest may interact with the C-terminal β-propeller blades of RACK1 in a manner akin to the interaction of the helical G-γ signal transducing protein with the β-propeller protein, G-β.
Updated Nonregulatory Guidance from the U.S. Departments of Education and Health and Human Services on Ensuring Educational Stability and Success for Students in Foster Care

This Information Memorandum (IM) notifies child welfare agencies about the release of updated nonregulatory guidance: Nonregulatory Guidance: Ensuring Educational Stability and Success for Students in Foster Care.

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 530016: 3,4-Dimethoxybenzaldehyde o-methyloxime

Chemical compound data from PubChem database. IUPAC Name: 1-(3,4-dimethoxyphenyl)-N-methoxymethanimine. Molecular Formula: C10H13NO3. Molecular Weight: 195.21. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Workforce Part 1 — The Workforce Development Framework

This Child Welfare Information Gateway Podcast is available on Apple Podcasts
  
  

, GooglePlay
  
  

, Spotify
  
  

, Stitcher
  
  

, SoundCloud
  
  

, and the Child Welfare Information Gateway
  
  

 website. Subscribe to receive new episodes as they are released.

Metadata-only record linking to the original dataset. Open original dataset below.
Patent AT-E401391-T1: [Translated] NEW STEROID-ACTIVATED NUCLEAR RECEPTORS AND USES THEREOF

A novel nuclear receptor, termed the steroid and xenobiotic receptor (SXR), a broad-specificity sensing receptor that is a novel branch of the nuclear receptor superfamily, has been discovered. SXR forms a heterodimer with RXR that can bind to and induce transcription from response elements present in steroid-inducible cytochrome P450 genes in response to hundreds of natural and synthetic compounds with biological activity, including therapeutic steroids as well as dietary steroids and lipids. Instead of hundreds of receptors, one for each inducing compound, the invention SXR receptors monitor aggregate levels of inducers to trigger production of metabolizing enzymes in a coordinated metabolic pathway. Agonists and antagonists of SXR are administered to subjects to achieve a variety of therapeutic goals dependent upon modulating metabolism of one or more endogenous steroids or xenobiotics to establish homeostasis. An assay is provided for identifying steroid drugs that are likely to cause drug interaction if administered to a subject in therapeutic amounts.
Table 18. Illicit Drug Dependence or Abuse in the Past Year, by Age Group and State: Percentages, Annual Averages Based on 2010 and 2011 NSDUHs

This report presents State estimates for measures of past year illicit drug dependence or abuse based on the combined 2010 and 2011 National Surveys on Drug Use and Health (NSDUHs). Resuts are provided by age group.
Patent AT-E399789-T1: [Translated] PRODUCTION OF PARTIALLY HYDROGENATED RAC-ANSA-METALLOCENE COMPLEXES

A process for the production of new partially hydrogenated metallocene complexes comprises reaction of optionally bridged transition metal complexes with cyclopentadienyl derivatives and at least partial hydrogenation with hydrogen in the presence of a catalyst.  A process for the production of partially hydrogenated metallocene complexes (I) comprises reaction of optionally bridged transition metal complexes of formula (1) with cyclopentadienyl derivatives of formula (2) at -78 to +250 degreesC, optionally in the presence of radicals or radical initiators to form a complex of formula (3) and at least partial hydrogenation with hydrogen in the presence of a catalyst. M  =  Ti, Hf, V, Nb, Ta, Cr, Mo, W, a Group 3 element or a lanthanide;  X  =  F, Cl, Br, I, H, 1-10C alkyl, 6-15C aryl, (1-10C)alkyl-(6-20C)aryl, -OR10 or -NR10R11;  n  =  1-4;  R1-R8, R', R  =  H, halo, 1-20C alkyl, 3-8 membered cycloalkyl optionally substituted by 1-10C alkyl, 6-15C aryl, (1-10C)alkyl-(6-20C)aryl, and neighboring R2-R7 optionally form 4-15C optionally unsaturated cyclic groups, -Si(R9)3, -OR10, -SR10, -N(R10)2 or -P(R10)2, optionally substituted by heteroatoms;  R9  =  1-20C alkyl, 3-6C cycloalkyl or 6-15C aryl optionally substituted by heteroatoms;  R10  =  1-10C alkyl, 6-15C aryl, 3-10C cycloalkyl, alkylaryl or Si(R)3;  R11  =  1-10C alkyl, 6-15C aryl, 3-10C cycloalkyl or alkylaryl;  Y, Y1  =  formula (4)-(9), =BR12, =AlR12, -Ge-, -Sn-, -O-, -S-, =SO, =SO2, =NR12, =CO, =PR12 or =P(O)R12;  R12  =  H, halo, 1-10C (fluoro)alkyl, 6-10C (fluoro)aryl, 1-10C alkoxy, 2-10C alkenyl, 7-40 C arylalkyl, alkylaryl or arylalkenyl or two R12 groups together with the atoms they are bonded to form a ring;  M1  =  Si, Ge or Sn;  m  =  0-3;  T  =  formula (10)-(12);  T'  =  formula (13)-(15);  R13, R13', R14, R14'  =  H, halo, 1-20C alkyl, 3-8 membered cycloalkyl optionally substituted by 1-10C alkyl, 6-15C aryl, (1-10C)alkyl-(6-20C)aryl, -OR10, -SR10, -N(R10)2, -P(R10)2 or Si(R9)3;  Z'  =  -(Q(R15)(R16))q-;  Q  =  Si, Ge, Sn or C;  R15, R16  =  1-10C alkyl, 3-10C cycloalkyl or 6-15C aryl;  q  =  1-4;  R17-R20, R17'-R20'  =  1-20C alkyl, 3-8 membered cycloalkyl optionally substituted by 1-10C alkyl, 6-15C aryl or alkylaryl whereby neighboring groups optionally form 4-15C cyclic groups or Si(R11)3;  M2  =  alkali- or alkaline earth metal cation; and p  =  1 or 2. An Independent claim is also included for racemic metallocene complexes of formula (3) where the  olefinic bonds of groups (10-(15) are hydrogenated.
Prolonged exposure of chromaffin cells to nitric oxide down-regulates the activity of soluble guanylyl cyclase and corresponding mRNA and protein levels

Background
          Soluble guanylyl cyclase (sGC) is the main receptor for nitric oxide (NO) when the latter is produced at low concentrations. This enzyme exists mainly as a heterodimer consisting of one α and one β subunit and converts GTP to the second intracellular messenger cGMP. In turn, cGMP plays a key role in regulating several physiological processes in the nervous system. The aim of the present study was to explore the effects of a NO donor on sGC activity and its protein and subunit mRNA levels in a neural cell model.
        
        
          Results
          Continuous exposure of bovine adrenal chromaffin cells in culture to the nitric oxide donor, diethylenetriamine NONOate (DETA/NO), resulted in a lower capacity of the cells to synthesize cGMP in response to a subsequent NO stimulus. This effect was not prevented by an increase of intracellular reduced glutathione level. DETA/NO treatment decreased sGC subunit mRNA and β1 subunit protein levels. Both sGC activity and β1 subunit levels decreased more rapidly in chromaffin cells exposed to NO than in cells exposed to the protein synthesis inhibitor, cycloheximide, suggesting that NO decreases β1 subunit stability. The presence of cGMP-dependent protein kinase (PKG) inhibitors effectively prevented the DETA/NO-induced down regulation of sGC subunit mRNA and partially inhibited the reduction in β1 subunits.
        
        
          Conclusions
          These results suggest that activation of PKG mediates the drop in sGC subunit mRNA levels, and that NO down-regulates sGC activity by decreasing subunit mRNA levels through a cGMP-dependent mechanism, and by reducing β1 subunit stability.
Managed Care Institutional Provider Network Data: September  30, 2014

This dataset contains institutional provider data. The primary purpose for the Provider Network Data System is to collect data needed to evaluate the provider networks including physicians, hospitals, labs, home health agencies, durable medical equipment providers, etc., for all types of Managed Care plans in New York State, including HIV Special Need Plans (SNP), Family Health Plus (FHP) Buy-In, Programs of All-Inclusive Care for the Elderly (PACE), and Non-PACE Managed Long-Term Care (MLTC) plans. For more information, check out: http://www.health.ny.gov/health_care/managed_care/.
2021 NSDUH Annual National Report

Read key findings from the 2021 National Survey on Drug Use and Health (NSDUH) on substance use, mental health, and treatment. Metrics in the report cover the civilian, noninstitutionalized US population ages 12 and older. Estimates are presented by age group and by race/ethnicity for selected measures. Unlike other NSDUH Annual National Reports, the 2021 report has no discussion of trends over time, because changes in survey methodology mean the indicators are not comparable to past NSDUH estimates.Along with the full report, a set of slides is available that displays the figures from the report.An errata document with corrected information was added in April 2023.
Patent AT-E400161-T1: [Translated] ELECTRIC HEATING UNIT HOUSED IN A CALORIE BATTERY BLOCK

Heating device having an electric heating body arranged within an accumulator block. The electric heating body includes an insulated flat resister. The accumulator block is structured and arranged to store calories. The heating device is adapted for use in a heating apparatus. This Abstract is not intended to define the invention disclosed in the specification, nor intended to limit the scope of the invention in any way.
South Carolina: 2011-2012 NSDUH

This report presents South Carolina\'s estimates for 25 measures of substance use and mental health based on the combined 2011 and 2012 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided by State and for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
CMS Program Statistics - Medicare Inpatient Hospital

The CMS Program Statistics - Medicare Inpatient Hospital tables provide use and payment data for all inpatient hospitals, including short-stay hospitals, critical access hospitals, long term care hospitals, inpatient psychiatric facilities, inpatient rehabilitation facilities, religious nonmedical health care institutions, children’s hospitals, and other hospitals. 

For additional information on enrollment, providers, and Medicare use and payment, visit the CMS Program Statistics page.

 

Below is the list of tables:


	MDCR INPT HOSP 1.  All Medicare Inpatient Hospitals:  Utilization, Program Payments, and Cost Sharing for Original Medicare Beneficiaries, by Type of Entitlement, Yearly Trend
	MDCR INPT HOSP 2.  All Medicare Inpatient Hospitals:  Utilization, Program Payments, and Cost Sharing for Original Medicare Beneficiaries, by Demographic Characteristics and Medicare-Medicaid Enrollment Status
	MDCR INPT HOSP 3.  All Medicare Inpatient Hospitals:  Utilization, Program Payments, and Cost Sharing for Original Medicare Beneficiaries, by Area of Residence
	MDCR INPT HOSP 4.  All Medicare Inpatient Hospitals:  Utilization, Program Payments, and Cost Sharing for Original Medicare Beneficiaries, by Type of Hospital
	MDCR INPT HOSP 5.  Medicare IPPS Short Stay Hospitals:  Utilization, Program Payments, and Cost Sharing for Original Medicare Beneficiaries, by Type of Entitlement, Yearly Trend
	MDCR INPT HOSP 6.  Medicare IPPS Short Stay Hospitals:  Utilization, Program Payments, and Cost Sharing for Original Medicare Beneficiaries, by Demographic Characteristics and Medicare-Medicaid Enrollment
	MDCR INPT HOSP 7.  Medicare IPPS Short Stay Hospitals:  Utilization, Program Payments, and Cost Sharing for Original Medicare Beneficiaries, by Area of Residence
	MDCR INPT HOSP 8.  Medicare IPPS Short Stay Hospitals:  Utilization and Program Payments for Original Medicare Beneficiaries, by Type of Entitlement and Total Days of Care
	MDCR INPT HOSP 9.  Medicare IPPS Short Stay Hospitals:  Utilization and Program Payments for Original Medicare Beneficiaries, by Location and Bedsize of Hospitals, by Medical School Affiliation, and Type of Control
	MDCR INPT HOSP 10.  Special-Category Hospitals: Utilization, Program Payments, and Cost Sharing for Original Medicare Beneficiaries, by Type of Hospital
Denver

Data tables consisting of Excel files with estimates, rates, relative standard errors, trends and confidence intervals, covering 2004-2011, for drug-related emergency department visits for the Denver Metropolitan Statistical Area. Tables are provided for 10 topics (\"analytic categories\") which are defined in the \"Guide to Drug Abuse Warning Trend Tables,\"  a separate document.   Each table includes data for over 500 drugs, including illicit drugs, prescription and over-the-counter medications, dietary supplements, inhalants and alcohol. Includes total visits, gender, age group, race/ethnicity, outcome of visit, drug combinations, number of drugs involved in visit, drug frequency, and drugs confirmed by toxicology. Additional detail is provided for illicit drugs, psychotherapeutic drugs, central nervous system (CNS) drugs, respiratory drugs and cardiovascular drugs.
Patent AT-E400238-T1: [Translated] SPINAL OSTEOSYNTHESIS DEVICE COMPRISING A CAGE, A FRONT PLATE AND TWO LONGITUDINAL RODS

A vertebral column osteosynthesis device of the type comprising at least one cage (1, 13) Containing a bone graft that will be substituted for at least one vertebra and the vertebrae (C2, C4, C7) between which the cage (1, 13) is placed, are fused with at least one anterior plate (17) that will be fixed to the said vertebrae (C2, C4) between which is cased the said case (1,13) or at least one of the said cages (1, 13) is placed, characterized in that the said device also comprises: Means (24, 25) of attachment of the said anterior plate (17) or at least one of the said anterior plates (17) to the cage (1) facing it; Two longitudinal rods (35, 36) that will extend along the vertebral column on each side of the processus spinosus, means of attachment of the ends of the said rods to healthy ends of the patient's skeleton, and means of connection of each rod to the said cage (1, 13) or to at least one of the said cages (1, 13).
IL-6 signaling by STAT3 participates in the change from hyperplasia to neoplasia in NRP-152 and NRP-154 rat prostatic epithelial cells

Background
          STAT3 phosphorylation is associated with the neoplastic state in many types of cancer, including prostate cancer. We investigated the role of IL-6 signaling and phosphorylation of STAT3 in 2 rat prostatic epithelial lines. NRP-152 and NRP-154 cells were derived from the same rat prostate, yet the NRP-152 cells are not tumorigenic while the NRP-154 cells are tumorigenic. These lines are believed to represent 2 of the stages in the development of prostate cancer, hyperplasia and neoplasia. Differences in signaling pathways should play a role in the 2 phenotypes, hyperplastic and neoplastic.
        
        
          Methods
          We looked at the phosphorylation state of STAT3 by intracellular flow cytometry, using phospho-specific antibodies to STAT3. We used the same method to examine IL-6 production by the cell lines. We also measured apoptosis by binding of fluorescent annexin V to the cells.
        
        
          Results
          Although both cells lines made IL-6 constitutively, phosphorylated-STAT3 was present in untreated NRP-154 cells, but not in NRP-152 cells. Treatment with dexamethasone inhibited the IL-6 production of NRP-152 cells, but enhanced that of NRP-154 cells. Treatment with the JAK2 inhibitor AG490 induced apoptosis in NRP-152, but not NRP-154 cells.
        
        
          Conclusions
          We conclude from these experiments that STAT3 activity plays a role in the phenotype of NRP-154 cell, but not NRP-152 cells. The significance of alternative IL-6 signaling pathways in the different phenotypes of the 2 cell lines is discussed.
Patent AT-E400098-T1: [Translated] METHOD FOR CONTROLLING RADIO MEANS

A method and apparatus is provided for transmitting a single counting end message to reject RRC connection requests of a plurality of terminals and for providing a quick response to terminals that transmitted a connection request. RRC connection request messages are sent by a plurality of terminals to a network in response to an RRC connection-required message received on a first channel. Each terminal monitors a second channel for an RRC connection setup message. The network establishes connections with a predetermined number of terminals by transmitting an RRC connection setup message on the second channel and transmits a single RRC connection-not-required message to the plurality of terminals on the first channel. Each terminal not receiving an RRC connection setup message after a predetermined period of time then terminates the network connection procedure and does not re-transmit an RRC connection request message after receiving the RRC connection-not-required message.
Report to Congress on the Effectiveness of CAPTA State Programs and Technical Assistance

This report to Congress provides an overview of how the 50 states, the District of Columbia, and the Commonwealth of Puerto Rico have targeted their Child Abuse Prevention and Treatment Act funds and how those choices evolve in response to ongoing assessments of state performance in ensuring the safety, permanency, and well-being of children and families involved in the child welfare system.

Metadata-only record linking to the original dataset. Open original dataset below.
Patent AT-E399541-T1: [Translated] EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONISTS FOR THE TREATMENT OF HIGHLY INCREASE MUCUS SECRETION IN THE LUNGS

Chemical patent from PubChem database. Patent Number: AT-E399541-T1. Title: Method of Treatment Using Chemical Compounds. Filing Date: 2014-06-26. Inventors: Patel, Amit, Jones, Michael. Abstract: Methods for treating diseases using specific chemical compounds are provided, including dosing regimens and combination therapies for enhanced therape... IPC Classifications: C07C, C07B, A61K. This patent covers 20 claims related to 9 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.
Patent AT-E400691-T1: [Translated] TEXTILE REFRESHMENT PROCESS SUITABLE FOR AN INTEGRATED HOUSEHOLD CLEANING AND TREATMENT PROCESS

An improved fabric article treatment method in a laundering appliance involving a fluid switchover step such that the first predominant fluid is at least partially removed and a second predominant fluid is added. Specifically, the first and the second predominant fluids are selected to have different dielectric constatns. The fluid switchover method is also useful in controlling the surfactant carryover in a laundering process.
HCUP Visualization of Inpatient Trends in COVID-19 and Other Conditions

The HCUP Visualization of Inpatient Trends in COVID-19 and Other Conditions displays State-specific monthly trends in inpatient stays related to COVID-19 and other conditions, and facilitates comparisons of the number of hospital discharges, the average length of stays, and in-hospital mortality rates across patient/stay characteristics and States. This information is based on the HCUP State Inpatient Databases (SID), starting with 2018 data, plus newer annual and quarterly inpatient data, if and when available.
Patent AT-E400650-T1: [Translated] METHOD FOR PRODUCING NUCLEIC ACID MOLECULES

Manufacturing a nucleic acid molecule comprising employing at least partially double-stranded oligonucleotide comprising a modification allowing the oligonucleotide to be coupled to a surface, a recognition site for a first type IIS restriction enzyme that cuts outside its recognition site, and a single-stranded overhang, is new. Manufacturing a nucleic acid molecule comprises: (a) providing a first at least partially double-stranded oligonucleotide which has a modification allowing the oligonucleotide to be coupled to a surface, comprises a recognition site for a first type IIS restriction enzyme that cuts outside its recognition site, and comprises a single-stranded overhang; (b) providing a second at least partially double-stranded oligonucleotide, which comprises a recognition site, its part or its complementary sequence, for a second type IIS restriction enzyme which cuts outside its recognition site, and comprises a single-stranded overhang; (c) ligating the first and the second oligonucleotide via their overhangs to generate a first ligation product; (d) immobilizing the first ligation product to the surface via the modification; (e) cutting the immobilized ligation product with the first type IIS restriction enzyme to release an elongated oligonucleotide having an overhang; (f) combining the elongated oligonucleotide with a further at least partially double-stranded oligonucleotide, which has a modification allowing the oligonucleotide to be coupled to a surface, a recognition site for a further type IIS restriction enzyme that cuts outside its recognition site, and a single-stranded overhang, and ligating the elongated second oligonucleotide and the further at least partially double-stranded oligonucleotide via their overhangs to form a further ligation product; (g) immobilizing the further ligation product to a surface via the modification; (h) cutting the further ligation product with the further type IIS restriction enzyme to release an elongated oligonucleotide having an overhang; and (i) optionally, repeating steps (f)-(h).